Skip to content
Peptigraph home

Tirzepatide for Liver Health: What the Evidence Shows

What human and animal studies show about Tirzepatide for liver health, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 / GIP dual agonistUpdated
Strongest evidence
Human RCT
Human studies
143
PubMed records, our ledger
Animal studies
15
PubMed records, our ledger
Studies we summarised
3
with an outcome for liver health

Evidence for liver health

Each row is an outcome related to liver health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Tirzepatide for liver health: outcomes in published studies
OutcomeResultStudy typeSource
Resolution of MASH without worsening of fibrosisMASH resolved without worsening fibrosis in 44% (5 mg), 56% (10 mg) and 62% (15 mg) vs 10% with placebo.Human RCTn = 190The New England journal of medicine 2024, PMID 38856224
Liver fat contentAbsolute liver fat fell by 8·09% with pooled tirzepatide 10 and 15 mg versus 3·38% with insulin degludec at week 52.Human RCTn = 296The lancet. Diabetes & endocrinology 2022, PMID 35468325
Visceral and abdominal fatTirzepatide significantly reduced liver fat content and visceral and abdominal subcutaneous adipose tissue volumes versus insulin degludec.Human RCTn = 296The lancet. Diabetes & endocrinology 2022, PMID 35468325
NASH biomarkersHigher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin (post hoc analysis).Human RCTDiabetes care 2020, PMID 32291277

PubMed records for Tirzepatide and liver health: 143 human, 15 animal (search counts, not studies we reviewed). Grades follow our evidence scale.

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 38856224

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Other peptides people research for liver health

SemaglutideBPC-157Kisspeptin-10
All peptides for liver health, compared

Common questions

Does Tirzepatide help with liver health?

The strongest study we summarise for liver health is human rct evidence, across 3 studies with an outcome for liver health. A trial result is not an approval; see the legal status.

Is Tirzepatide approved for liver health?

Tirzepatide is FDA approved (Mounjaro, Zepbound). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for liver health?

There is no single answer. Our liver health overview compares each candidate by evidence grade and legal status rather than by popularity.

More on Tirzepatide

DosageDoses used in published studies, with the source for each.CalculatorVial, water and dose to syringe units.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.

Sources

  1. 1Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.The New England journal of medicine · 2024PMID 38856224Accessed 2 Oct 2026
  2. 2Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.The lancet. Diabetes & endocrinology · 2022PMID 35468325Accessed 2 Oct 2026
  3. 3Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.Diabetes care · 2020PMID 32291277Accessed 2 Oct 2026

Found an error? Report a correction.